Monopar Therapeutics MNPR
NASDAQ MNPR
$72.35 -1.88 (-2.53%)
At close: Oct 21, 2026 · 4:00 PM EDT

Monopar Therapeutics (MNPR) Short term Debt (2020)

Updated

Monopar Therapeutics (MNPR) posted Short term Debt of $67,772 for Q3 2020, up 43.0% from the prior quarter.

Analysis

Monopar Therapeutics (MNPR) Short term Debt (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Monopar Therapeutics 613.90 Mn 332.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 67,772.00
Jun 30, 2020 47,379.00
API Access

Monopar Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=MNPR&period=max&api_key=YOUR_API_KEY